Kindred Biosciences to Announce First Quarter 2017 Financial Results

Kindred Biosciences to Announce First Quarter 2017 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, May 3, 2017 San Francisco, CA (April 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today […]

Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit

San Francisco, CA (March 16, 2017) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will be presenting at the 2017 Jefferies Animal Health Summit in New York, NY on Thursday, March 30, 2017 at 10:45 AM […]

Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotion Pathology

San Francisco, CA (March 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotion Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of […]

Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results

San Francisco, CA (March 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016. “We are very pleased with the progress of Mirataz™ and Zimeta™, including the recently announced approval […]

Kindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 1, 2017 San Francisco, CA (February 21, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and […]